EMBJ: Held by 1 Biotech Hedge Fund (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Home›Companies›EMBRAER S.A. (EMBJ)

EMBRAER S.A.

EMBJ

Held by 1 specialist biotech fund

1 fund opened new positions. Short interest: 1.1% of float.

Aerospace & DefenseCEO: Francisco Gomes NetoIPO: 2025Website ↗

A Brazilian aerospace and defense company that designs, develops, manufactures and services commercial, executive and agricultural aircraft, plus defense & security systems and eVTOL technologies.

Score Holdings Short Interest Catalysts Insiders Research

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Feedback

Signal Score

3.2/10

1 fund opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 1 specialist fund●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

Driehaus CapitalHeld 7Q ↑

Position history (shares)

Driehaus Capital

AI Signal

Signal Note: Not Applicable

This filing reflects a growth-oriented fund increasing exposure to Embraer S.A., an aerospace manufacturer, not a biotech company. The signal lacks relevance to biotech sector analysis and contains no drug development, clinical catalyst, or dilution risk data pertinent to life sciences investing.

Unlock full AI analysis — 14-day free trial

7 quarters

Position Trend

May 15, 2025

$94.6M

1 fund

Aug 14, 2025

$44.8M

1 fund

Nov 14, 2025

$56.2M

1 fund

Feb 17, 2026

$102.3M

1 fund

+482% total institutional value over 12 quarters

Short Interest

Short Shares

1.75M

Change

-14.3%

Days to Cover

1.0

% of Float

1.1%

Settlement

Apr 15, 2026

Short interest over 5 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Position Details

Driehaus CapitalINCREASEFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

11 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

LRCX1 fund LRMR1 fund SWIM1 fund TVTX1 fund TARS1 fund TER1 fund GHM1 fund AGYS1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer